2016
Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A
Hartley M, Bourreau E, Rossi M, Castiglioni P, Eren R, Prevel F, Couppié P, Hickerson S, Launois P, Beverley S, Ronet C, Fasel N. Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A. PLOS Pathogens 2016, 12: e1005852. PMID: 27658195, PMCID: PMC5033371, DOI: 10.1371/journal.ppat.1005852.Peer-Reviewed Original ResearchIL-17AMurine modelMetastatic leishmaniasisDisease chronicityHuman patientsInflammatory cytokines IL-17AIL-17A inhibitionPotent innate immunogenPresence of LRV1Cytokines IL-17AAbsence of IFNMetastatic complicationsImmunologic mechanismsStandard therapyCytokines IFNPrognostic valueOpen ulcerationDisease outcomeCutaneous leishmaniasisSecondary sitesSignificant associationLeishmania parasitesTherapeutic promiseLeishmaniasisLRV1
2012
Leishmania RNA virus: when the host pays the toll
Hartley M, Ronet C, Zangger H, Beverley S, Fasel N. Leishmania RNA virus: when the host pays the toll. Frontiers In Cellular And Infection Microbiology 2012, 2: 99. PMID: 22919688, PMCID: PMC3417650, DOI: 10.3389/fcimb.2012.00099.Peer-Reviewed Original ResearchConceptsToll-like receptor 3Mucocutaneous leishmaniasisHyper-inflammatory immune responseLeishmania parasitesPotent innate immunogenExperimental animal modelsType 1 interferonLeishmania RNA virusAnti-leishmanial drugsMetastatic leishmaniasisDestructive inflammationMetastatic complicationsMetastatic diseaseInflammatory cascadeInflammatory stateRNA virusesSecondary lesionsImmune responseAnimal modelsClinical isolatesDisease severityReceptor 3Leishmania guyanensisMetastatic factorsClinical interventions